Ho-jin Y. Shin

Ansan, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 181 publications

Effects of Foot Progression Angle and Stance Width on Lower-Limb Muscle Activation During the Holding Phase of Forward Lunge Exercises in Healthy Adults: A Randomized Within-Participant Crossover Study.

Effects of Foot Progression Angle and Stance Width on Lower-Limb Muscle Activation During the Holding Phase of Forward Lunge Exercises in Healthy Adults: A Randomized Within-Participant Crossover Study.

Journal: Journal of clinical medicine
Published: June 15, 2026

Immediate Changes in Physical Function, Psychological Health, and Health-Related Quality of Life Following a Five-Day Multicomponent Coastal Health Program in Postmenopausal Women: A Randomized Controlled Trial.

Immediate Changes in Physical Function, Psychological Health, and Health-Related Quality of Life Following a Five-Day Multicomponent Coastal Health Program in Postmenopausal Women: A Randomized Controlled Trial.

Journal: Journal of clinical medicine
Published: June 09, 2026

Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients.

Role of Autologous Stem Cell Transplantation in Transplant-Eligible Dialysis-Dependent Multiple Myeloma Patients.

Journal: Cancer research and treatment
Published: May 12, 2026

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Journal: Blood
Published: April 30, 2026

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Journal: Lancet (London, England)
Published: March 18, 2026

Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).

Randomized Phase II Study of Bortezomib, Lenalidomide, and Dexamethasone (VRD) Versus Lenalidomide and Dexamethasone (RD) in Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM1910).

Journal: Cancer research and treatment
Published: March 11, 2026

Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma.

Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma.

Journal: International journal of hematology
Published: February 24, 2026

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.

Second Salvage Autologous Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Multiple Myeloma in the Era of Novel Agents: Results of the KMM2301 Study.

Journal: Cancers
Published: January 06, 2026

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Journal: Blood
Published: January 05, 2026

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Annals of hematology
Published: December 22, 2025

Tenofovir Alafenamide Promotes Differentiation and Induces Apoptosis of AML Cells by Inhibiting Telomerase Reverse Transcriptase.

Tenofovir Alafenamide Promotes Differentiation and Induces Apoptosis of AML Cells by Inhibiting Telomerase Reverse Transcriptase.

Journal: Anticancer research
Published: December 02, 2025

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 20, 2025
Showing 1-12 of 181

Last Updated: 09/26/2026